− この都医学研セミナーは終了しました。 −
|演者||Ph.D Khalid Iqbal（New York State Institute for Basic Research in Developmental Disabilities）|
|世話人||楯林 義孝 副参事研究員（うつ病プロジェクト）|
Cerebral aging is a major public health problem in modern society. Currently, 25 to 35 million people are estimated to be suffering from Alzheimer disease (AD) and this number is expected to triple by 2050 unless some effective treatment that can prevent or cure this major cause of dementia in middle to old age individuals is developed. To date, other than symptomatic drugs which help provide some symptomatic rescue for a relatively short term, no disease-modifying drugs for AD are available. A major challenge in developing effective AD therapeutics is the multifactorial nature of the disease and involvement of several different mechanisms. Three major approaches that are currently under development are (1) inhibition of neurodegeneration with small molecules against different targets, (2) clearance of pathological polypeptides, i.e., A? and abnormally hyperphosphorylated tau, by immunotherapy, and (3) shifting of the balance from neurodegeneration to regeneration of the brain.